We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson Commercially Launches Precise WTA Kits
Read MoreHide Full Article
Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis (WTA) kits commercial available. These kits give an easier way of identifying and quantifying genetic information in individual cells for genomics-based research.
Over the past one year, BD returned almost 21.76%, which is higher than the Zacks categorized Medical/Dental Supplies sub-industry’s gain of roughly 3.59%. Also, a long-term expected earnings growth rate of 10.02% instills some confidence in investors.
The estimate revision trend also seems quite favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement, indicating chances of continued steady performance ahead. Notably, the current fiscal year estimate for the stock stands at $9.49 per share.
Coming back to the news, the WTA kits are typically used by researchers in the discovery phase of genes. BD Precise WTA kits include specialized reagents that can extract RNA molecules from individual cells to enable researchers to count each individual instance of the molecule.
Based in Franklin Lakes, NJ, Becton, Dickinson is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating the expansion of the company’s product portfolio. The company also has a partnership with Central Admixture Pharmacy Services (CAPS) under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes. We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results.
Zacks Rank & Key Picks
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold).
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock posted an impressive one-year return of 137.6%.
ARIAD Pharmaceuticals projects sales growth of 28.9% for the current year. Additionally, the company posted a promising one-year return of almost 348.6%.
Penumbra has a long-term expected earnings growth rate of approximately 20%. Notably, the stock witnessed an impressive one-year return of 52.7%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Becton, Dickinson Commercially Launches Precise WTA Kits
Leading global medical technology company Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis (WTA) kits commercial available. These kits give an easier way of identifying and quantifying genetic information in individual cells for genomics-based research.
Over the past one year, BD returned almost 21.76%, which is higher than the Zacks categorized Medical/Dental Supplies sub-industry’s gain of roughly 3.59%. Also, a long-term expected earnings growth rate of 10.02% instills some confidence in investors.
The estimate revision trend also seems quite favorable for the stock at this moment, with one estimate moving up in the last 60 days and no downward movement, indicating chances of continued steady performance ahead. Notably, the current fiscal year estimate for the stock stands at $9.49 per share.
Coming back to the news, the WTA kits are typically used by researchers in the discovery phase of genes. BD Precise WTA kits include specialized reagents that can extract RNA molecules from individual cells to enable researchers to count each individual instance of the molecule.
Based in Franklin Lakes, NJ, Becton, Dickinson is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
An innovative product pipeline is the key growth driver at BD. A huge number of regulatory approvals both in the U.S. and international markets are facilitating the expansion of the company’s product portfolio. The company also has a partnership with Central Admixture Pharmacy Services (CAPS) under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre-filled anesthesia syringes. We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results.
Zacks Rank & Key Picks
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector include Addus Glaukos Corporation (GKOS - Free Report) , ARIAD Pharmaceuticals, Inc. and Penumbra Inc. (PEN - Free Report) . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock posted an impressive one-year return of 137.6%.
ARIAD Pharmaceuticals projects sales growth of 28.9% for the current year. Additionally, the company posted a promising one-year return of almost 348.6%.
Penumbra has a long-term expected earnings growth rate of approximately 20%. Notably, the stock witnessed an impressive one-year return of 52.7%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>